Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

Wyeth Pharmaceuticals Continues Licensing Spree

  • Inovio Biomedical granted Wyeth Pharmaceuticals a worldwide nonexclusive license to its DNA delivery technology for intramuscular applications of certain therapeutic DNA vaccines. Inovio will exclusively supply Wyeth with electroporation devices for the vaccines included in the license agreement.

    Under the terms of the agreement, Inovio will receive a $4.5-million upfront license fee, annual license maintenance fees, research support, up to $60 million in payments based on successful completion of clinical and regulatory milestones, and royalties on the sale of products covered by the license. 

    This comes after Wyeth Pharmaceuticals signed a $212.5-M exclusive research collaboration and license agreement with Ablynx regarding Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »